2023
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
Foldi J, Tsagianni A, Salganik M, Schnabel C, Brufsky A, van Londen G, Pusztai L, Sanft T. Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer. BMC Cancer 2023, 23: 606. PMID: 37391697, PMCID: PMC10314405, DOI: 10.1186/s12885-023-11104-w.Peer-Reviewed Original ResearchConceptsAdjuvant endocrine therapyEarly-stage hormone receptor-positive breast cancerHormone receptor-positive breast cancerReceptor-positive breast cancerEndocrine therapyBreast cancerLate breast cancer recurrenceExtended endocrine therapyNon-persistence ratesIntolerable side effectsBone density scanBreast cancer recurrenceHigher likelihoodRate of persistenceElectronic health recordsConclusionsIn patientsMedication persistenceTreatment persistenceLow patientsMetastatic recurrenceCancer recurrenceCommon reasonSide effectsPatientsStage I
2022
The Breast Cancer Index Registry Study: Initial analysis of the first 1,000 patients.
O'Shaughnessy J, Encarnacion C, O'Neal B, Wong J, Siuliukina N, Sanft T, Jankowitz R, Pegram M, Treuner K, Fox J. The Breast Cancer Index Registry Study: Initial analysis of the first 1,000 patients. Journal Of Clinical Oncology 2022, 40: e12513-e12513. DOI: 10.1200/jco.2022.40.16_suppl.e12513.Peer-Reviewed Original ResearchBreast Cancer IndexExtended endocrine therapyLate distant recurrenceBreast cancer patientsRegistry studyEndocrine therapyDistant recurrenceClinicopathological factorsMedication adherenceCancer patientsHigh riskLower riskHormone receptor-positive breast cancer patientsReceptor-positive breast cancer patientsEarly-stage breast cancer patientsNCCN Clinical Practice GuidelinesLong-term clinical outcomesPositive breast cancer patientsAssociated clinicopathological factorsAdjuvant endocrine therapyNode-negative patientsNode-positive patientsPrognostic risk groupsClinical practice guidelinesRoutine clinical care
2020
Adherence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor (HR)-positive breast cancers.
Foldi J, Schnabel C, Salganik M, Pusztai L, Sanft T. Adherence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor (HR)-positive breast cancers. Journal Of Clinical Oncology 2020, 38: 527-527. DOI: 10.1200/jco.2020.38.15_suppl.527.Peer-Reviewed Original ResearchLate distant recurrenceAdjuvant endocrine therapyEndocrine therapyDistant recurrenceDXA scansBreast cancerHigh riskStage IEarly-stage hormone receptorExtended endocrine therapyIntolerable side effectsOsteopenia/osteoporosisPositive breast cancerRate of adherenceSerious adverse effectsBreast cancer recurrenceMajority of ptsHigher likelihoodElectronic health recordsLocal recurrenceMedian ageLate recurrenceMetastatic recurrenceTumor characteristicsMedication adherence
2019
A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making
Sanft T, Berkowitz A, Schroeder B, Hatzis C, Schnabel C, Brufsky A, Gustavsen G, Pusztai L, Londen G. A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making. Breast Cancer Management 2019, 8: bmt22. DOI: 10.2217/bmt-2019-0001.Peer-Reviewed Original Research
2015
Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy.
Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna M, Abu-Khalaf M, Chung G, Silber A, Hofstatter E, Mougalian S, Epstein L, Hatzis C, Schnabel C, Pusztai L. Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy. Journal Of Clinical Oncology 2015, 33: 538-538. DOI: 10.1200/jco.2015.33.15_suppl.538.Peer-Reviewed Original Research